Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shoichi Ohwada

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|August 4, 2016
Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trialShoichi Ohwada, Satoshi Morita
Journal of Pharmacokinetics and Pharmacodynamics|January 29, 2021
Concentration-QTc analysis for single arm studiesYasushi Orihashi, Shoichi Ohwada, Yuji Kumagai
Journal of Pain Research|August 9, 2020
Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week StudyMasayuki Baba, Hiroshi Takatsuna, Norimitsu Matsui, et al.
Journal of Diabetes Investigation|January 24, 2019
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patientsMasayuki Baba, Norimitsu Matsui, Masanori Kuroha, et al.
Pain and Therapy|February 14, 2020
Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, StudyMasayuki Baba, Masanori Kuroha, Shoichi Ohwada, et al.
Journal of Diabetes Investigation|November 14, 2019
Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic painMasayuki Baba, Norimitsu Matsui, Masanori Kuroha, et al.
Medicine|September 9, 2020
Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trialJitsu Kato, Norimitsu Matsui, Yoshihiro Kakehi, et al.
Pain|March 27, 2019
Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patientsJitsu Kato, Norimitsu Matsui, Yoshihiro Kakehi, et al.
Clinical Therapeutics|June 1, 2021
Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III StudiesJitsu Kato, Masayuki Baba, Masanori Kuroha, et al.
Clinical Pharmacology in Drug Development|April 18, 2018
A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian VolunteersMendel Jansen, Steven Warrington, Victor Dishy, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|August 4, 2016
Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trialShoichi Ohwada, Satoshi Morita
Journal of Pharmacokinetics and Pharmacodynamics|January 29, 2021
Concentration-QTc analysis for single arm studiesYasushi Orihashi, Shoichi Ohwada, Yuji Kumagai
Journal of Pain Research|August 9, 2020
Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week StudyMasayuki Baba, Hiroshi Takatsuna, Norimitsu Matsui, et al.
Journal of Diabetes Investigation|January 24, 2019
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patientsMasayuki Baba, Norimitsu Matsui, Masanori Kuroha, et al.
Pain and Therapy|February 14, 2020
Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, StudyMasayuki Baba, Masanori Kuroha, Shoichi Ohwada, et al.
Journal of Diabetes Investigation|November 14, 2019
Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic painMasayuki Baba, Norimitsu Matsui, Masanori Kuroha, et al.
Medicine|September 9, 2020
Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trialJitsu Kato, Norimitsu Matsui, Yoshihiro Kakehi, et al.
Pain|March 27, 2019
Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patientsJitsu Kato, Norimitsu Matsui, Yoshihiro Kakehi, et al.
Clinical Therapeutics|June 1, 2021
Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III StudiesJitsu Kato, Masayuki Baba, Masanori Kuroha, et al.
Clinical Pharmacology in Drug Development|April 18, 2018
A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian VolunteersMendel Jansen, Steven Warrington, Victor Dishy, et al.
Pageof 2